News | Breast Imaging | July 09, 2020

When and How to Monitor for Breast Cancer After Childhood Chest Radiation

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Simulation finds starting at age 30 with MRI and mammography to be the preferred strategy; starting at 25 prevented marginally more deaths, but with more testing and emotional stress

Getty Images

July 9, 2020 — Chest radiation is used to treat children with Hodgkin and non-Hodgkin lymphoma as well as lung metastases in various solid tumors. But radiation itself is a potential cancer risk, including an increased risk for breast cancer later in life. Girls receiving chest radiation for childhood cancer face a breast cancer risk as high as 30 percent by age 50.

What is the best strategy for catching these breast cancers early? Annual screening with mammography and breast MRI is recommended, but practices vary from location to location, and the benefits, harms, and costs are unclear. A new study led by Jennifer M. Yeh, Ph.D., in the Division of General Pediatrics at Boston Children's Hospital, used modeling to compare results of different approaches. The findings appear in the Annals of Internal Medicine.

"Randomized clinical trials are often thought of as the 'gold standard,' but they aren't always feasible for screening studies, especially in rare high risk groups such as survivors of childhood cancer," Yeh said. "However, those developing guidelines need information on the potential benefits and harms of screening. Decision modeling can provide important insight on these health outcomes."

Yeh, with collaborators across the country, used two breast cancer simulation models that were developed to guide screening recommendations for women who are not cancer survivors. The two models, part of the Cancer Intervention and Surveillance Modeling Network (CISNET), were adapted using information from the Childhood Cancer Survivor Study (CCSS). The CCSS is a cohort study on outcomes, including breast cancer, in more than 24,000 survivors of childhood and adolescent cancers diagnosed between 1970 and 1999.

The models evaluated the following annual screening strategies:

  • no screening
  • digital mammography and breast MRI, starting at age 25 (as per current recommendations of the Children's Oncology Group), 30 or 35
  • MRI only, starting at age 25, 30, or 35.

The models assumed that women who were screened continued to be screened until age 74, and that those diagnosed with breast cancer received the best therapy available at the time.

All annual screening approaches save lives

In the simulation, Yeh showed that without screening, childhood cancer survivors previously treated with chest radiation had a 10 to 11 percent lifetime risk of dying from breast cancer, as compared with a 2.5 percent risk among women in the general population.

Compared with no screening, all annual screening strategies prevented more than half of breast cancer deaths according to the models. A combined approach of both breast MRI and mammography, beginning at age 25, prevented the most deaths (an estimated 56 to 71 percent); MRI alone prevented slightly fewer (56 to 62 percent).

However, starting at age 25 also meant more screening tests, more false-positive findings, and more breast biopsies that turned out to be benign. For example, the researchers estimate that the average survivor screened with both MRI and mammography would have four to five false-positive screens and one to two breast biopsies over the course of her lifetime.

When the emotional stress and costs of additional screening and testing were factored into the analysis, starting at age 30 was the preferred strategy; relatively little was gained by starting at age 25. Either strategy reduced the risk of dying from breast cancer by at least half, with or without the addition of mammography to MRI.

Interpreting the findings

Lisa Diller, M.D., chief medical officer of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, is an expert in the care of childhood cancer survivors and a co-author of the study. "Breast cancer screening is one of the most important issues that oncologists should discuss with survivors of childhood chest radiation," Diller said. "Having these data informs discussions with young women who are facing screening at a very young age. It both reassures them that waiting until age 30 might be reasonable and impresses upon them that this screening could be life-saving."

One limitation of the study was that it used data from childhood cancer survivors diagnosed between 1970 and 1986. Since then, cancer treatment has changed, including decreased doses and improved delivery of radiation, and breast cancer monitoring now includes digital breast tomosynthesis, also known as 3D mammography.

"Our model-based findings suggest that even if the risk of breast cancer declines by half with more recent changes in radiation dose and delivery, early initiation of screening still remains favorable for these high-risk survivors," Yeh said. "Ensuring survivors are aware of and have access to screening can save lives."

For more information: www.childrenshospital.org/

Related Content

Culturally relevant strategies are necessary to improve preventive health care in this rapidly growing population, Rutgers researchers say

Getty Images

News | Women's Health | October 28, 2020
October 28, 2020 — Indian and Pakistani women are diagnosed with...
Study of Penn Medicine patients shows abbreviated MRI may be a valuable supplemental screening for women with dense breasts
News | MRI Breast | October 28, 2020
October 28, 2020 — Beth Reisboard, 76, was relieved in 2018 when she received the results from her annual...
Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will